deltatrials
Completed PHASE1 NCT01885338

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia

Sponsor: American Psychiatric Foundation

Conditions Schizophrenia
Interventions Inactive placebo capsule N-acetylcysteine (NAC)
Updated 6 times since 2017 Last updated: Jun 2, 2015 Started: Jun 30, 2013 Primary completion: May 31, 2014 Completion: May 31, 2014

This PHASE1 trial investigates Schizophrenia and is currently completed. American Psychiatric Foundation leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Psychiatric Foundation
  • VA Greater Los Angeles Healthcare System
  • VISN 22 Mental Illness Research, Education, and Clinical Center
Data source: VA Greater Los Angeles Healthcare System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Los Angeles, United States